|
The National Cancer Policy Board was established in 1997 at the Institute of Medicine and National Research Council to address broad policy issues that effect cancer in the United States and to recommend ways to advance the nation's effort against cancer. The board, consisting of 20 members drawn from outside the federal government, includes health care consumers, providers, and researchers in a variety of disciplines in the sciences and humanities.
The board meets quarterly to review progress, discuss emerging issues and gather information and views from private and public sector actors, including many federal and state agencies that sponsor or conduct related work. The board analyzes information and issues reports and recommendations, prepared under its direction by professional staff members, and may commission papers and hold workshops in support of those projects. It also oversees reports prepared by committees appointed for a specific task.
The Chairman of the National Research Council appoints board members for their expertise, experience, and constituencies, generally serving 3-year terms. The board is funded primarily under contract with the National Cancer Institute, with co-funding from the Centers of Disease Control and Prevention. Several other organizations provide funding for the overall work of the board: The American Cancer Society, UnitedHealth Group Foundation, the American Society of Clinical Oncology, Abbot, Aventis, and Amgen; and other organizations have supported specific projects.
|